Tag: KRAS
-
R-nuucell joins EP PerMed to validate cancer therapy
R-nuucell selected by EP PerMed to validate a promising cancer therapy Portuguese biotechnology startup R-nuucell has been chosen to participate in the European Union’s EP PerMed program, a six-month initiative designed to advance precision medicine for cancer and other diseases. The Lisbon-based company was among eight startups selected for the program, which funds innovative projects…
-
R-nuucell chosen by EU EP PerMed to validate cancer therapy
R-nuucell among eight startups chosen for the EP PerMed six-month program The European program EP PerMed has selected eight innovative biotech ventures to advance personalized medicine, allocating six months of dedicated support and funding. The eight projects cover a range of cancer-related and genetic tools, rehabilitation, and tissue recovery solutions. Among them is the Portuguese…